A lthough it has been ≈50 years since Ross and Braunwald 1 reported the malignant natural history of aortic stenosis (AS) after the onset of angina, syncope, or heart failure, the pathophysiologic underpinnings of these classic symptoms remain incompletely delineated. We appreciate that angina may occur in the absence of epicardial coronary disease with both increased demand and impaired supply, contributing to imbalance of the supply-demand relationship. Exertional syncope reflecting the inability to maintain cerebral perfusion is attributed to an inability to increase cardiac output in combination with, at times, paradoxically reduced systemic vascular resistance. Although we attribute the low-output symptoms of heart failure to the same inability to increase cardiac output, we still have an incomplete understanding of the changes that restrict stroke volume augmentation. Similarly, although the dyspnea of heart failure is typically linked to elevated pulmonary capillary pressures, which of the multiple pathways leading to elevated pulmonary pressures is/are operative in the symptomatic patient with AS? Although afterload mismatch and attendant left ventricular (LV) systolic dysfunction provide a substrate for symptoms in some patients, understanding the basis for symptoms in patients with preserved LV ejection fraction (EF) is particularly challenging because measures of AS severity alone predict the onset of but correlate imperfectly with the presence of symptoms. 2
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In this issue of Circulation: Cardiovascular Imaging, Dahl et al 3 provide hypothesis-generating data that argue an important role for LV remodeling and diastolic dysfunction in the pathogenesis of symptoms in patients AS and preserved (≥50%) LVEF. They compared echocardiographic parameters in 139 asymptomatic patients assessed in an outpatient clinic and 99 symptomatic patients referred for surgical intervention. Although the symptomatic patients were surprisingly younger, had less atrial fibrillation, hypertension, and chronic lung disease than did the asymptomatic cohort, higher LV mass index and relative wall thickness, advanced diastolic dysfunction (restrictive filling pattern and shorter mitral deceleration time), and left atrial dilation were all more common in the symptomatic patients after correction for AS severity and comorbidities. It is important that these observations held after patients with atrial fibrillation were excluded because the assessment of diastolic function in such patients is difficult with no consensus as to the best way to compensate for beat-to-beat variability (averaging versus matching of beats by cycle length versus single beat approaches). The observations of this study argue that LV hypertrophy (LVH) and diastolic dysfunction may underlie symptoms in those with severe AS and preserved LVEF. As with prior studies, neither aortic valve area nor mean gradient differed between patients with versus without symptoms.
These results are intuitively appealing, particularly in suggesting an explanation for AS-associated dyspnea. LVH and attendant increased LV stiffness, advanced diastolic dysfunction, and left atrial enlargement all provide indirect evidence of a causal link between pathological hypertrophy and diastolic dysfunction and elevated left-sided filling pressures causing dyspnea. LVH with increased relative wall thickness (concentric LVH) in combination with smaller end-diastolic volumes provides a substrate for an inability to augment stroke volume to meet the demands of exercise and thus the low output symptoms of heart failure and syncope. LVH also unfavorably influences both the supply and demand components of the supply-demand relationship in ways that would predispose to angina.
However, closer scrutiny of the data and comparison with a similar study by Park et al 4 argue that the story may be more complicated than this interpretation suggests. Park et al used data from a prospective registry to evaluate hemodynamic patterns for symptomatic presentations of severe AS (defined, as in the Dahl study, by an aortic valve area, <1 cm2 in patients with an LVEF>50%). They compared those with syncope (n=15), dyspnea (n=110), or chest pain (n=32) with one another, as well as with 341 patients who were asymptomatic. Unlike the Dahl study, they did not observe overall increased left atrial volume index, relative wall thickness, or LV mass index in the symptomatic patients but did note that E/e' (a measure of pulmonary capillary wedge pressure) was higher in the symptomatic group and that cardiac output was lower. In the Dahl study, neither E/e' nor cardiac index differentiated between symptomatic and asymptomatic patients. In the Park subanalysis, left atrial volume index was greater in those with dyspnea and chest pain than in those with syncope and E/e' was greater in those with dyspnea than in those with syncope. Mitral deceleration time and overall patterns of diastolic function were not reported by Park. There are important differences between the Dahl and Park study groups that may account for these differing results. The Park patients were younger with reverse age differentials between symptomatic and symptomatic patients when compared with the Dahl study. In the Park study, mean ages were 68 and 65 years in symptomatic and asymptomatic patients versus 72 and 76 years, respectively, in the Dahl study. Sex distribution was similar. Because the Dahl symptomatic cohort was identified from patients referred to surgery as opposed to a prospective registry, surgical selection bias may be an issue. Limited data as to how the decision for surgery was made may also account for the fact that the Dahl study has limited breakdown on presenting symptoms, although we are told that only 3 patients had syncope. Differences in the prevalence of dyspnea, chest pain, and syncope as presenting symptoms might also lead to seemingly conflicting results. Finally, racial differences may also play a role with the Park cohorts drawn from Korea versus the Dahl patients being Danish.
One other notable difference between the Dahl and Park studies is in the overall prevalence and degree of LVH. In the Park study, the LV mass index was 145 and 140 g/m 2 in the symptomatic versus asymptomatic groups as opposed to 120 and 95 g/m 2 in comparable Dahl study groups. It is difficult to attribute the much greater LV mass index in the Park study to associated hypertension because only 48% and 43% of symptomatic and asymptomatic patients, respectively, had hypertension versus 40% and 73% in the Dahl study. In the Dahl study, hypertension was statistically more common in the asymptomatic group, something that seems counterintuitive given the relative prevalence of LVH. This highly variable degree of LVH for seemingly comparable increases in afterload is, however, consistent with prior reports. 5 Finally in the Dahl study, coronary disease was present in 22% of asymptomatic versus 16% of symptomatic patients, whereas in the Park study 48% of the overall study group had coronary disease. This may be another important difference between the 2 study groups and one that would be expected to influence the prevalence of chest pain as a presenting complaint. In aggregate, the variability between the Park and Dahl study groups speaks to the heterogeneity of the patient population with severe AS and the challenges of conducting a study that will deliver one-size-fits-all results.
As noted by Dahl et al, other methodologic issues should be considered in determining the generalizability of their results. First, as the authors note, Doppler tissue imaging of the mitral annulus is limited by calcification that damps motion. Because annular calcification has been reported in 25% of patients with severe AS, E/e' estimates of pulmonary capillary wedge pressure may be invalid in many patients with AS. 6 A more significant concern is that the absence of symptoms was accepted from patients self-reporting with no systematic use of stress testing in either the Dahl or Park studies. It is increasingly understood that with conditions such as AS, which progress insidiously, patients might subconsciously scale back their activities to avoid exertional fatigue and dyspnea or attribute subtle changes in exercise tolerance to aging. It is notable that the asymptomatic patients in the Dahl study were older and more likely to have atrial fibrillation and chronic lung disease, comorbidities to which symptoms of heart failure might be erroneously attributed. In addition, the more frequent use of diuretics and angiotensin-converting enzyme/angiotensin receptor blocker in the asymptomatic group also begs the question of whether these patients were truly asymptomatic. Thus, although the patients and their treating physicians may have thought that there were no symptoms attributed to their AS, it would be useful to have more objective confirmation that this was the case. Although the authors argue that having an asymptomatic group contaminated by truly symptomatic patients would underestimate the differences between groups, this is speculative.
BNP determinations would have been interesting in that symptomatic patients, particularly those with dyspnea and worse diastolic function, might have been expected to have increased BNP levels. Multiple studies have examined BNP levels in patients with diastolic dysfunction. [7] [8] [9] [10] [11] Lubien et al reported higher BNP levels in patients with diastolic dysfunction compared with normal controls, and B-type natriuretic peptide (BNP) levels were the highest in patients with restrictive filling, characterized by shortened deceleration times as noted by Dahl. 8 In each category of diastolic dysfunction, patients with symptoms of heart failure had higher BNP levels. BNP and N-terminal pro-BNP have been shown to be able to predict moderate to severe diastolic dysfunction as determined by Doppler echocardiography in patients with heart failure and normal ejection fraction. 9 Gerber et al 10 also showed a correlation between BNP and symptom onset in patients with AS with symptomatic patients having higher BNP levels after adjustment for age, sex, serum creatinine, aortic valve area, and LVEF. When the subgroup of patients with severe AS (aortic valve area, ≤1.0 cm 2 ) and LVEF of ≥50% were examined, asymptomatic patients had lower N-proBNP levels when compared with those with symptoms (data for BNP not provided). Bergler-Klein et al 11 reported that the asymptomatic patients with severe AS and LVEF >50% who developed symptoms during 377±150-day follow-up had higher baseline BNP and N-terminal pro-BNP levels when compared with patients who remained asymptomatic. At follow-up, both neurohormones increased further in patients who developed symptoms but did not change in those who remained asymptomatic. Thus, there is a clear association between symptoms and BNP levels in patients with severe AS and preserved LVEF. BNP levels would be an interesting component of future studies as a means of supporting patient classification (symptomatic or asymptomatic) and providing a reproducible quantitative measure to compare with echocardiographic variables.
Conclusions
AS is a common clinically important disease for which the major indication for intervention (surgical or catheter-based) is the onset of symptoms. Although not definitive, the study of Dahl et al provides data that collectively speak to the adaptation of the left ventricle rather than the severity of AS as the determinant of symptoms. This provocative study provides a framework for future work in this area. Although both the Dahl and Park studies suggest that diastolic dysfunction may be an important correlate of symptoms, the match between diastolic abnormality and symptom seems to be inconsistent. This is in keeping with the variable correlation between echocardiographic indices of diastolic function and symptom status in other disease states. 12 Given the heterogeneity of the patient group with AS, it would be difficult for any single site to amass study groups large enough to address the many variables that confound our ability to establish cause-effect relationship. Most important are coronary disease, hypertension, and rhythm disorders, such as atrial fibrillation. Registries allowing multi-institution participation with common data elements should be developed. Prospective categorization of symptoms would also be important and the recognition that patients can present with >1 symptom. Given the interaction between systemic blood pressure and AS, determinations of valvuloarterial impedance should be included. Stress echocardiography could confirm asymptomatic status and provide the opportunity to assess the systolic and diastolic responses to stress. Luckily these tools, along with the previously mentioned BNP, are readily available. In addition, the era of translational research offers the possibility of single-site studies that would extend the evaluation of the ventricular responses to the cellular and subcellular levels.
Longitudinal studies will also be essential to provide stronger evidence of the links between hemodynamics and symptom onset or progression by, in effect, using each patient as his/her own control. Indeed such studies might allow us to revisit the Ross and Braunwald paradigm with the hypothesis that there are presymptomatic predictors of adverse outcomes, possibly including those noted in the study of Dahl et al. These might ultimately be added to symptoms of angina, chest pain, and heart failure as indications for surgery.
